BRPI0911384A2 - cannabinoids in combination with non-cannabinoid chemotherapeutic agents (eg alkylating agents or serm) - Google Patents

cannabinoids in combination with non-cannabinoid chemotherapeutic agents (eg alkylating agents or serm)

Info

Publication number
BRPI0911384A2
BRPI0911384A2 BRPI0911384A BRPI0911384A BRPI0911384A2 BR PI0911384 A2 BRPI0911384 A2 BR PI0911384A2 BR PI0911384 A BRPI0911384 A BR PI0911384A BR PI0911384 A BRPI0911384 A BR PI0911384A BR PI0911384 A2 BRPI0911384 A2 BR PI0911384A2
Authority
BR
Brazil
Prior art keywords
serm
cannabinoids
combination
agents
chemotherapeutic agents
Prior art date
Application number
BRPI0911384A
Other languages
Portuguese (pt)
Inventor
Guillermo Velasco Diez
Manuel Guzman Pastor
Mar Lorente
Sofia Torres
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Publication of BRPI0911384A2 publication Critical patent/BRPI0911384A2/en
Publication of BRPI0911384A8 publication Critical patent/BRPI0911384A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0911384A 2008-06-04 2009-06-04 CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (FOR EXAMPLE, ALKYLATION AGENTS OR SERM) BRPI0911384A8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810203.0A GB2460672B (en) 2008-06-04 2008-06-04 Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
PCT/GB2009/050620 WO2009147438A1 (en) 2008-06-04 2009-06-04 Cannabinoids in combination with non -cannabinoid chemotherapeutic agents (e.g. serm or alkylating agents)

Publications (2)

Publication Number Publication Date
BRPI0911384A2 true BRPI0911384A2 (en) 2015-12-29
BRPI0911384A8 BRPI0911384A8 (en) 2018-04-03

Family

ID=39638156

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911384A BRPI0911384A8 (en) 2008-06-04 2009-06-04 CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (FOR EXAMPLE, ALKYLATION AGENTS OR SERM)

Country Status (24)

Country Link
US (3) US20110086113A1 (en)
EP (2) EP2320881B1 (en)
JP (2) JP5674649B2 (en)
KR (1) KR20110053944A (en)
CN (1) CN102083426B (en)
AR (1) AR072002A1 (en)
AU (1) AU2009254935B2 (en)
BR (1) BRPI0911384A8 (en)
CA (1) CA2726257C (en)
CO (1) CO6341551A2 (en)
DK (1) DK2320881T3 (en)
ES (2) ES2887084T3 (en)
GB (2) GB2475183B (en)
IL (1) IL209739A0 (en)
MX (1) MX2010013036A (en)
MY (1) MY156264A (en)
NZ (1) NZ589373A (en)
PT (1) PT2320881T (en)
RU (1) RU2543034C2 (en)
SG (1) SG191643A1 (en)
TW (1) TWI469777B (en)
UA (1) UA104589C2 (en)
WO (1) WO2009147438A1 (en)
ZA (1) ZA201008558B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2554592B (en) * 2010-03-12 2018-07-11 Gw Pharma Ltd A glioma treatment Comprising Temozolomide with a mixture of THA and CBD ar a ration of 1:1
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
KR102427777B1 (en) 2012-06-26 2022-08-01 델 마 파마슈티컬스 Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
GB201217285D0 (en) * 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
WO2014168986A1 (en) 2013-04-08 2014-10-16 Brown Dennis M Therapeutic benefit of suboptimally administered chemical compounds
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
DK3122426T3 (en) 2014-03-28 2023-04-03 Univ Duke Treatment of breast cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
EP3250200A4 (en) 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US20170189373A1 (en) * 2015-05-15 2017-07-06 Andrew Hospodor Terpene Control in Scaleable Cannabinoid Medicinal Formulations
CA3187317A1 (en) * 2015-10-27 2017-05-04 Jay Pharma, Inc. Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
AU2016359160A1 (en) 2015-11-24 2018-06-14 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
CN111629724A (en) * 2017-09-02 2020-09-04 科学控股公司 Tetrahydrocannabinol modulators
WO2020160452A1 (en) * 2019-02-01 2020-08-06 Tess Ventures, Inc. Combining serms, sarms, and cannabinoids for improving safety and efficacy of endocrine therapies
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
US20220362168A1 (en) * 2019-08-09 2022-11-17 Jay Pharma Inc. Administration regimes of cannabinoids in combination with chemotherapeutics against cancer
WO2021034405A1 (en) * 2019-08-19 2021-02-25 Diverse Biotech, Inc. Platinum complex anti-neoplastic agents comprising a cannabinoid ligand

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2164584A1 (en) * 2000-02-11 2002-02-16 Univ Madrid Complutense Therapy with cannabinoids in the treatment of cerebral tumor
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
RU2166948C1 (en) * 2000-05-29 2001-05-20 Центральный научно-исследовательский рентгенорадиологический институт Method for treating gliomae aggravated with epileptic syndrome
EP1326996A4 (en) * 2000-09-14 2005-08-24 Univ California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
DE10051427C1 (en) * 2000-10-17 2002-06-13 Adam Mueller Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (en) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmaceutical composition.
US20080057117A1 (en) * 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) * 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
US7285687B2 (en) * 2002-04-25 2007-10-23 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
AU2006231452B2 (en) * 2005-04-01 2011-05-26 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
JP2008540570A (en) * 2005-05-13 2008-11-20 ユニメッド・ファーマシューティカルズ・インコーポレーテッド Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
KR100675281B1 (en) * 2005-09-05 2007-01-29 삼성전자주식회사 Semiconductor device having decoupling capacitor and method of fabricating the same
WO2008144475A1 (en) * 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
UA71391U (en) * 2012-01-05 2012-07-10 Харьковский Государственный Университет Питания И Торговли Method for producing processed cheese spread

Also Published As

Publication number Publication date
EP3213748B1 (en) 2021-08-18
KR20110053944A (en) 2011-05-24
GB0810203D0 (en) 2008-07-09
US20110086113A1 (en) 2011-04-14
EP2320881B1 (en) 2017-09-20
CN102083426A (en) 2011-06-01
ES2887084T3 (en) 2021-12-21
SG191643A1 (en) 2013-07-31
UA104589C2 (en) 2014-02-25
RU2543034C2 (en) 2015-02-27
JP2011522028A (en) 2011-07-28
GB2460672B (en) 2012-01-04
AU2009254935A1 (en) 2009-12-10
AU2009254935B2 (en) 2015-03-19
CA2726257A1 (en) 2009-12-10
MX2010013036A (en) 2011-02-18
TW201002316A (en) 2010-01-16
GB201101072D0 (en) 2011-03-09
TWI469777B (en) 2015-01-21
ZA201008558B (en) 2014-11-26
CA2726257C (en) 2016-09-13
US20210069333A1 (en) 2021-03-11
GB2460672A (en) 2009-12-09
DK2320881T3 (en) 2018-01-02
BRPI0911384A8 (en) 2018-04-03
EP2320881A1 (en) 2011-05-18
JP2015057411A (en) 2015-03-26
JP5674649B2 (en) 2015-02-25
NZ589373A (en) 2013-05-31
US20190099492A1 (en) 2019-04-04
GB2475183B (en) 2011-11-23
ES2653200T3 (en) 2018-02-06
CO6341551A2 (en) 2011-11-21
WO2009147438A1 (en) 2009-12-10
CN102083426B (en) 2015-05-13
IL209739A0 (en) 2011-02-28
AR072002A1 (en) 2010-07-28
MY156264A (en) 2016-01-29
PT2320881T (en) 2017-12-22
GB2475183A (en) 2011-05-11
EP3213748A1 (en) 2017-09-06
RU2010154672A (en) 2012-07-20

Similar Documents

Publication Publication Date Title
BRPI0911384A2 (en) cannabinoids in combination with non-cannabinoid chemotherapeutic agents (eg alkylating agents or serm)
GB2504241B (en) Droplet-based assay system
ZA200810621B (en) Detecting sub-system
BRPI0820483A2 (en) GLYCHAMYLASE VARIANTS WITH CHANGED PROPERTIES
BRPI0917980A2 (en) power-boosting subchannel
HK1189937A1 (en) Distinguishing assay
EP2294227A4 (en) Concentration assay
BRPI0807911A2 (en) ALFA2C ADRENORRECEPTOR AGONISTS
BRPI0917472A2 (en) Herbicidal combination with dimethoxytriazinyl substituted difluoromethanesulfonylanilides
BRPI0923865A2 (en) absorbent articles with multiple indication widths
BRPI0917673A2 (en) Herbicide-protective combination comprising dimethoxytriazinyl substituted difluoromethanesulfonylanilides
GB0811567D0 (en) Assay
GB0807534D0 (en) Assay
GB0803850D0 (en) Assay
GB0811858D0 (en) Assay
GB0809262D0 (en) Assay
GB0812845D0 (en) Electrochemical assay
GB0822261D0 (en) Assay
GB0821624D0 (en) Assay
GB0814591D0 (en) Assay
DE602007003078D1 (en) Sliding plate with reinforced slot
FR2925053B3 (en) MARKING REAGENTS
GB0822260D0 (en) Assay
GB0822010D0 (en) Assay
ES1067602Y (en) EURO TICKET IDENTIFIER

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO LIMITED (JP)

Owner name: GW PHARMA LIMITED (GB) , OTSUKA PHARMACEUTICAL CO

B25A Requested transfer of rights approved

Owner name: GW PHARMA LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: GW PHARMA LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements